Clinical trial · Interventional
Biparametric MRI in Prostate Cancer Screening: a Noninferior Randomized Controlled Study
NCT05025527CI-TRIAL-00061805unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single centre non-inferiority randomized controlled trial in comparison of the bpMRI between the traditional pathway in prostate cancer screening
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biparametric MRI (bpMRI) | Diagnostic Test | — | UNRESOLVED |
| Prostate cancer antigen (PSA) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- bpMRI
- description
- Man receive the bpMRI for Prostate cancer(PCa) screening
- interventionNames
- Diagnostic Test: biparametric MRI (bpMRI)
- type
- ACTIVE_COMPARATOR
- label
- PSA
- description
- Man receive the PSA blood test for Prostate cancer screening
- interventionNames
- Diagnostic Test: Prostate cancer antigen (PSA)
Primary outcomes (1)
- measure
- The proportion of men with clinically significant cancer
- timeFrame
- Within 1 month after the biopsy
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 50 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. age between 18 and 80 years old 2. life-expectancy at least 10 years 3. fully understand the clinical trial protocol and sign the informed consent; Exclusion Criteria: 1. Already diagnosis with prostate cancer; 2. cannot tolerate prostate biopsy or has contraindication to biopsy; 3. cannot tolerate prostate biopsy or has contraindication to MRI examination; 4. undergo biopsy within 1 year 5. patients judged by the investigator to be unsuitable to participate in the clinical trial;
References
Publications (0)
Data not yet available
No reference posted for this study.